Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
23 studies found for:    "Noonan syndrome 5"
Show Display Options
RSS Create an RSS feed from your search for:
"Noonan syndrome 5"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
Condition: Hepatitis C
Interventions: Drug: daclatasvir;   Drug: asunaprevir;   Drug: Ribavirin
2 Completed Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
Condition: Hepatitis C, Chronic
Interventions: Drug: IDX719;   Drug: Placebo
3 Completed An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
Condition: Hepatitis C Virus
Intervention:
4 Not yet recruiting Phase 3b, Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg;   Drug: Ribavirin 200Mg Tablet
5 Active, not recruiting A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Condition: Chronic Hepatitis C
Interventions: Drug: ravidasvir hydrochloride;   Drug: sofosbuvir;   Drug: ribavirin
6 Completed Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/VOX;   Drug: SOF/VEL
7 Not yet recruiting A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
Condition: HCV
Interventions: Drug: elbasvir/grazoprevir;   Drug: Sofosbuvir;   Drug: Ribavirin
8 Completed Ph IIA Study (SOC +/- NS5B)
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325;   Drug: Placebo;   Drug: Peg-interferon alfa-2a;   Drug: Ribavirin
9 Completed TD-6450 SAD and MAD in Healthy Subjects
Condition: Hepatitis C
Interventions: Drug: TD-6450;   Drug: Placebo
10 Completed TD-6450 MAD Study in HCV Infected Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: TD-6450;   Drug: Placebo
11 Completed A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Condition: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: Drug: PPI-461;   Drug: Placebo
12 Completed A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-383;   Drug: Placebo
13 Unknown  A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
Condition: Chronic Hepatitis C Infection
Interventions: Drug: JNJ-47910382 30 mg;   Drug: JNJ-47910382 90 mg;   Drug: JNJ-47910382 200 mg;   Drug: Placebo
14 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
15 Completed Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668;   Drug: BI 207127 Dose 1;   Drug: BI 207127 Dose 2;   Drug: Faldaprevir;   Drug: Ribavirin;   Drug: BI 207127 Placebo
16 Terminated Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Placebo;   Drug: JNJ-47910382
17 Completed A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: HCV Infection
Interventions: Drug: GS-5885;   Drug: Placebo
18 Completed A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-668;   Drug: Placebo
19 Completed Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
20 Completed A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.